Sea You at Fetch Long Beach
Logo Image
|Videos|July 28, 2022

Fetch faculty shares insight on new canine cancer treatment

Kansas City

In a dvm360® interview, Sue Ettinger, DVM, DACVIM (Oncology), highlights an innovative, effective method for treating mast cell tumors

During this dvm360® interview, Sue Ettinger, DVM, DACVIM (Oncology)—also known as "Dr Sue Cancer Vet"—describes the science behind Stelfonta (tigilanol tiglate injection), an alternative treatment to surgery for canine mast cell tumors. She excitedly divulges how a similar option is proving effective for other species, including humans.

A partial transcript of the interview is below. View the video for more of the discussion.

Sue Ettinger, DVM, DACVIM (Oncology): It's really exciting that [Stelfonta], this innovative brand new drug that just got FDA approved, in the end of 2020 . . . it's been available in clinic since February of 2021. But it's also being used to treat human cancers, and I think that's really exciting as well. In case you do mixed animal [medicine], there are a couple of case reports in using it for some of the cutaneous tumors in horses like sarcoids and melanoma.

Register for our Fetch dvm360® Conference in Kansas City conference from August 26-28 here.

Related to this article

View more
Q&A: Caregiver burden can begin early in pet illness. Are veterinary teams equipped to support clients, and how can veterinary social workers help both parties?
Q&A: Caregiver burden can begin early in pet illness. Are veterinary teams equipped to support clients, and how can veterinary social workers help both parties?
Caroline Cox, LSW, MSW, and Erika Krick, VMD, DACVIM (Oncology), discuss the role of veterinary social workers in supporting clients, communicating with veterinary teams, and helping practices address the human side of veterinary care in this Q&A from an interview at the 2026 Fetch National Harbor Veterinary Conference.
Read more
Laverdia now available for purchase for dogs with lymphoma
Laverdia now available for purchase for dogs with lymphoma
Verdinexor tablets are now available for dogs with lymphoma after receiving full FDA approval earlier this year, offering an at-home treatment option given twice weekly and showing a longer time to disease progression than the control in a field study.
Read more